Sentences with phrase «clinical year at»

After a clinical year at Louisiana State University, she moved back to San Diego and recently started at Carlsbad Animal Hospital after completing a rotating internship.As a veterinarian, Candace particularly enjoys emergency medicine and surgery.

After graduating from Ross University School of Veterinary Medicine with a D.V.M. degree, she served her clinical year at the University of Missouri, College of Veterinary Medicine.

Although born and raised in Port Orchard, Dr. Dietrich attended Ross University located in the Caribbean to earn her veterinary degree, completing her senior clinical year at Kansas State University.

She received her DVM from St. Matthew's University School of Veterinary Medicine (2012), and completed a clinical year at Purdue University's Veterinary Teaching Hospital.

Dr. Cesario then attended Ross University Veterinary School, with a clinical year at the University of Wisconsin.

She finished her clinical year at the University of Minnesota Veterinary College.

I finished my clinical year at the University of Wisconsin in Madison.

She was accepted into Ross Veterinary School in 2010 and finished her clinical year at Purdue Veterinary School.

Upon completing the coursework in St. Kitts, he and his family moved to Cary, NC where Dr. Reyes completed his clinical year at North Carolina State University in May 2016 and began practicing with Banfield in June of 2016.

She graduated from Cornell University in 1995, and went on to continue her veterinary training at Ross University, finishing up her clinical year at Louisiana State University.

She attended veterinary school at Ross University School of Veterinary Medicine, on the Caribbean island of St. Kitts, and completed her clinical year at the prestigious Purdue University.

In 2004, Dr. Scott began classes at Ross University School of Veterinary Medicine in St. Kitts, West Indies, and in 2007 completed her clinical year at the University of Florida College of Veterinary Medicine.

Dr. Fiocchi completed her clinical year at Tufts University where she developed her interest in internal medicine.

She graduated from Ross University in January 2013 and finished her clinical year at Louisiana State University.

He completed his clinical year at the University of Missouri in Columbia, MO..

Originally from Chicago, she attended Ross University School of Veterinary Medicine and finished her clinical year at the University of Illinois School of Veterinary Medicine in 2004.

He received his degree in Veterinary Medicine from Ross University, and completed his clinical year at the University of Minnesota.

She completed her clinical year at the University of Minnesota.

He graduated from Ross University School of Veterinary Medicine in 2007, after completing his clinical year at the University of Minnesota.

She was graduated with Honors from Ross University, then completed a post - doctoral clinical year at Purdue University before entering private practice.

Dr. Toso then received her Doctor of Veterinary Medicine degree from Ross University, and completed her clinical year at Cornell University.

Dr. Luker moved to Texas in 2012 and completed her clinical year at Texas A&M University with a focus on Mixed Animal Medicine.

Dr. Peters is a 2009 graduate of Ross University School of Veterinary Medicine and she completed her clinical year at Colorado State University's College of Veterinary Medicine and Biomedical Sciences.

Dr. Larson spent her clinical year at the University of Missouri College of Veterinary Medicine and completed cardiology and dentistry externships at the University of Pennsylvania School of Veterinary Medicine.

After graduating from the University of Massachusetts, Dr. Scheider received his Doctorate of Veterinary Medicine from Ross University in 2007, and he completed his clinical year at the University of Missouri.

I attended Veterinary School at Ross University in St. Kitts with my clinical year at Kansas State, graduating with honors in 2013.

Dr. Read completed his veterinary education at St. George's University in Grenada, West Indies and his clinical year at Washington State University.

When the lecture portion of her studies was completed she moved to Lafayette, Indiana where she completed her clinical year at Purdue University College of Veterinary Medicine.

She graduated from Ross University School of Veterinary Medicine and did a clinical year at North Carolina State University.

She spent her clinical year at the University of Minnesota where she practiced medicine at the Minnesota Zoo, The Raptor Center, and The Wildlife Rehabilitation Center.

She has graduated with Honors from Ross University, then completed a post - doctoral clinical year at Purdue University before entering private practice.

Dr.Longo then completed her clinical year at Louisiana State University, in Baton Rouge.

In 2006 she obtained her Doctorate of Veterinary Medicine from Ross University after spending her clinical year at Cornell University.

She did her clinical year at the University Of Minnesota College Of Veterinary Medicine.

Dr. Elbrecht performed her clinical year at the University of Missouri in 2010.

She was graduated with Honors from Ross University, and then completed a post - doctoral clinical year at Purdue University.

Dr. Rachel Moon received her DVM in 2003 from St. George's University in Grenada, West Indies, after completing her clinical year at the Auburn University College of Veterinary Medicine.

She completed her clinical year at Oklahoma State University.

During her clinical years at NCNM, Dr. Noel interned at Outside In, a clinic that focuses on the health of at risk youth and homeless teens.

Dr. Hefter completed his clinical years at Cornell University then began his career as a licensed veterinarian in sunny South Florida.

Not exact matches

«We had been offering our Depression Care service for a number of years, and we wanted to dig into our data and measure our impact... look and see who our end users were,» says Barb Vader, Vice President, Clinical Services at Morneau Shepell, and the study's research lead.

In an editorial about Theranos in the journal Clinical Chemistry and Laboratory Medicine earlier this year, Eleftherios P. Diamandis, the head of clinical biochemistry at Mount Sinai Hospital in Toronto, argued that fingerprick tests are not necessarily any more painful than needle draws — though there still might be an appeal for someone afraid of Clinical Chemistry and Laboratory Medicine earlier this year, Eleftherios P. Diamandis, the head of clinical biochemistry at Mount Sinai Hospital in Toronto, argued that fingerprick tests are not necessarily any more painful than needle draws — though there still might be an appeal for someone afraid of clinical biochemistry at Mount Sinai Hospital in Toronto, argued that fingerprick tests are not necessarily any more painful than needle draws — though there still might be an appeal for someone afraid of needles.

The M.N. Nurse Practitioner program at the University of British Columbia, home to one of the top ranked undergraduate nursing programs in the country, requires applicants to have at least three years of clinical experience and a well - demonstrated ability to act autonomously — a critical skill for primary care practitioners.

To get in, you need to be a registered nurse with a nursing degree and at least two years of clinical experience.

Actual results and the timing of events could differ materially from those anticipated in the forward - looking statements due to these risks and uncertainties as well as other factors, which include, without limitation: the uncertain timing of, and risks relating to, the executive search process; risks related to the potential failure of eptinezumab to demonstrate safety and efficacy in clinical testing; Alder's ability to conduct clinical trials and studies of eptinezumab sufficient to achieve a positive completion; the availability of data at the expected times; the clinical, therapeutic and commercial value of eptinezumab; risks and uncertainties related to regulatory application, review and approval processes and Alder's compliance with applicable legal and regulatory requirements; risks and uncertainties relating to the manufacture of eptinezumab; Alder's ability to obtain and protect intellectual property rights, and operate without infringing on the intellectual property rights of others; the uncertain timing and level of expenses associated with Alder's development and commercialization activities; the sufficiency of Alder's capital and other resources; market competition; changes in economic and business conditions; and other factors discussed under the caption «Risk Factors» in Alder's Annual Report on Form 10 - K for the fiscal year ended December 31, 2017, which was filed with the Securities and Exchange Commission (SEC) on February 26, 2018, and is available on the SEC's website at www.sec.gov.

«We look very different today than five years ago — for example, clinical and technology professionals are the first and third largest job categories across UnitedHealth Group — and we will look different again five years from now as we continue to evolve at an accelerated pace,» UnitedHealth CEO David Wichmann said on the company's first - quarter conference call.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

Athenex, which raised $ 68 million from a secondary stock offering during the quarter, finished the year with $ 51 million in cash and short - term investments, down from $ 69 million in September as the company spent heavily on clinical trials for the drugs it is developing and absorbed higher licensing fees at its specialty drug business, which has added 12 new drugs to its stable of products.

Founder Elizabeth Holmes, who is facing a two - year ban by U.S. regulators from running a clinical testing company, used the session at the American Association for Clinical Chemistry's annual scientific meeting to introduce the «miniLab» testing device, a 95 - pound diagnostic tool that can fit on a tclinical testing company, used the session at the American Association for Clinical Chemistry's annual scientific meeting to introduce the «miniLab» testing device, a 95 - pound diagnostic tool that can fit on a tClinical Chemistry's annual scientific meeting to introduce the «miniLab» testing device, a 95 - pound diagnostic tool that can fit on a tabletop.

All of them undergo at least one year's clinical training in family counseling before becoming accredited counselors.